SS-31 / elamipretide dosing schedule
> Updated:
Human schedule
SS-31 (elamipretide) is given by subcutaneous injection once daily after reconstitution. The figures below are a reference generalized from clinical studies and physician-supervised protocols, not a dosing plan.
This is a concise reference to regimens described for adults; it is not an individual prescription.
SS-31 (elamipretide) dosage differs noticeably between clinical trials and research-protocol summaries, so the clinical reference and the research range are shown separately below.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 2–5 mg subcutaneously, once daily | Starting dose |
| Standard range | 5–10 mg subcutaneously, once daily | Increase if needed |
| Upper protocol range | 10–20 mg subcutaneously, once daily | Maximum in this schedule |
| Clinical trials | 40 mg subcutaneously, once daily | Reference from trials |
Practical dosing and effect details
The 'clinical trials, 40 mg' row in the table above is not a rough estimate, it comes from an actual protocol. In Thompson and colleagues' study (Genetics in Medicine, 2021), known as TAZPOWER, patients with Barth syndrome first received subcutaneous elamipretide at 40 mg per day or placebo for 12 weeks in a crossover design with a washout pause between arms, purely for trial control. Participants then moved to continuous daily 40 mg dosing with no further pauses; over 168 weeks of that extension, they walked on average 96 meters further on the 6-minute walk test versus baseline.
It was the long continuous phase, not the initial short one, that produced the measurable result: by the researchers' design, the peptide's mitochondrial effect depends on a steady daily presence of the compound in the body rather than on a single concentration peak.
This is reference information from a published trial, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.